Corvus Pharmaceuticals, Inc. — Director's Dealing 2021

Sep 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2021-09-09

Reporting Person: MILLER RICHARD A MD (Director, President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-09	Stock Option (Right to Buy)	$2.60	A	320000	Acquired	2031-09-09	Common Stock (320000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-forty eighth (1/48th) of the shares subject to the option in successive, equal monthly installments measured from September 9, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.